Literature DB >> 6228520

Suppressor cells induced by BCG release non-specific factors in vitro which inhibit DNA synthesis and interleukin-2 production.

V Colizzi, J Ferluga, F Garreau, M Malkovsky, G L Asherson.   

Abstract

Mice injected intravenously with a high dose (5 X 10(7) ) of BCG fail to develop delayed hypersensitivity to BCG and are described as anergic or unresponsive. Spleen cells from these mice release factors on culture which suppress DNA synthesis induced by concanavalin A in vitro. Cell separation experiments showed that both macrophages and T cells produce inhibitory factors. However, the macrophage factor has a molecular weight 10,000-30,000, while the T cell factor has a molecular weight of 50,000-70,000. Further evidence that these two factors are different is provided by the kinetics of their action. The T cell factor only acts when given within 12 hr of stimulation with concanavalin A, while the macrophage factor acts even when given at 48 hr. In the case of the T cell factor, the inhibition of DNA synthesis may be attributed to its ability to block the interleukin-2 production induced by Con A. As similar T cell and macrophage factors are produced in mice responding to simple chemically reactive haptenes (contact sensitizers), it is possible that a similar suppressor circuit is involved in the control of the response to contact sensitizers and in the production of unresponsiveness (anergy) in mice given large doses of BCG.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6228520      PMCID: PMC1454412     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  [Spleen reactivity after BCG treatement: test and strain dependency of the response].

Authors:  I Florentin; S Orbach-Arbouys
Journal:  Ann Immunol (Paris)       Date:  1977 Jan-Mar

2.  Suppressor T-cells in BCG-infected mice.

Authors:  F M Collins; S R Watson
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

3.  Nonspecific macrophage suppressor factor: its role in the inhibition of contact sensitivity to picryl chloride by specific T suppressor factor.

Authors:  W Ptak; M Zembala; M Hanczakowski-Rewicka; G L Asherson
Journal:  Eur J Immunol       Date:  1978-09       Impact factor: 5.532

Review 4.  Anergy and infection.

Authors:  W E Bullock
Journal:  Adv Intern Med       Date:  1976

5.  Induction of suppressor T cells in delayed-type hypersensitivity to Mycobacterium bovis BCG in low-responder mice.

Authors:  R M Nakamura; T Tokunaga
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

6.  Inhibition of contact sensitivity by macrophages.

Authors:  W Ptak; M Zembala; G L Asherson; J Marcinkiewicz
Journal:  Int Arch Allergy Appl Immunol       Date:  1981

7.  Immune response to persistent mycobacterial infection in mice.

Authors:  F M Collins; N E Morrison; V Montalbine
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

8.  Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in Mycobacterium lepraemurium infection.

Authors:  A Hoffenbach; P H Lagrange; M A Bach
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

9.  Purification of murine T cell growth factor. A lymphocyte mitogen with helper activity.

Authors:  A Granelli-Piperno; J D Vassalli; E Reich
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

10.  Active suppression of 1-fluoro-2,4-dinitrobenzene-immune T cells. Requirement of an auxiliary T cell induced by antigen.

Authors:  M S Sy; S D Miller; J W Moorhead; H N Claman
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Why intracellular parasitism need not be a degrading experience for Mycobacterium.

Authors:  D G Russell; S Sturgill-Koszycki; T Vanheyningen; H Collins; U E Schaible
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-09-29       Impact factor: 6.237

2.  Induction by an immunogenic immunomodulating agent of nonspecific T cell suppression of lymphocyte responsiveness in MLR but not of antibody production.

Authors:  C Reuben; D Halperin; S Ben-Efraim; D W Weiss
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Mechanisms underlying the depressed production of interleukin-2 in spleen and lymph node cell cultures of mice infected with Mycobacterium bovis BCG.

Authors:  R Turcotte; D Legault
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

4.  Recombinant human interleukin-2 reverses in vitro-deficient cell-mediated immune responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients.

Authors:  H Shiratsuchi; Y Okuda; I Tsuyuguchi
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

5.  Dissociation between interleukin-1 and interleukin-2 production in proliferative response to microbial antigens: restorative effect of exogenous interleukin-2.

Authors:  D Vismara; G Lombardi; E Piccolella; V Colizzi
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

6.  In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice.

Authors:  V Colizzi
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

7.  Unresponsiveness to Con A in spleen cell cultures of M. lepraemurium-infected mice is dependent on a defective expression of high-affinity IL-2 receptors rather than on a lack of IL-2 production.

Authors:  R Turcotte; S Lemieux
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

8.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

9.  Mannan-specific and mannan-induced T-cell suppressive activity in patients with chronic mucocutaneous candidiasis.

Authors:  A Durandy; A Fischer; F Le Deist; E Drouhet; C Griscelli
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

10.  BCG immunotherapy in stage I melanoma patients. Does it influence prognosis determined by HLA-DR expression in high-risk primary tumors?

Authors:  E B Bröcker; L Suter; B M Czarnetzki; E Macher
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.